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ABSTRACT
Mutations in β-catenin are traditionally described as late events in thyroid 
cancer progression. However, the functional implications of β-catenin dysregulation 
in the context of tumor initiating events remain unclear. The aim of this work was to 
investigate whether the two main oncogenic drivers in thyroid cancer, RAS and BRAF, 
could activate the Wnt/β-catenin pathway. Expression of HRASV12 but not BRAFV600E in 
thyroid cells induced β-catenin nuclear localization, increased β-catenin-dependent 
transcriptional activity and inhibited GSK3β. In a panel of human thyroid cancer cell 
lines representative of the main genetic events in thyroid cancer, β-catenin activation 
was highly dependent on PI3K/AKT activity through its phosphorylation at S552, 
but not on MAPK. Silencing of β-catenin expression in cell lines led to a dramatic 
reduction in proliferation due to an induction of senescence, which was concordant 
with a reduction in tumor size in nude mice. Moreover, β-catenin silencing suppressed 
the expression of EMT-related genes and reduced the invasive capacity of the tumor 
cells. In conclusion, this work demonstrates that RAS-driven tumors induce PI3K/
AKT-dependent β-catenin activation.
INTRODUCTION
The most recent advances in thyroid cancer 
research emerge from an increased understanding of the 
mechanisms that control thyroid cell proliferation and 
differentiation, and the associated signal transduction 
pathways [1]. The current model of thyroid cancer 
development assumes that accumulation of mutations in 
tumor cells drives progression through a dedifferentiation 
process that leads initially to well-differentiated 
carcinomas, such as papillary (PTC) and follicular (FTC) 
thyroid carcinoma, and progresses to poorly differentiated 
(PDC) and undifferentiated or anaplastic (ATC) thyroid 
carcinomas [2, 3]. Initiation and progression of thyroid 
cancer comprises multiple genetic alterations, of which 
mutations leading to the activation of the MAPK and 
PI3K/AKT signaling pathways are the most studied. In 
PTC, MAPK activation is crucial for tumor initiation. 
Characterized defects in this pathway include mutations 
in the intracellular signal transducers RAS and BRAF, 
and rearrangements in the cell-membrane tyrosine 
kinase receptors RET (RET/PTC); these mutations are 
mutually exclusive [4–8]. In FTC, PI3K/AKT activation 
is thought to arise from RAS mutations, inactivating 
mutations in the PTEN or RASL1 tumor suppressor 
genes, or by activating mutations in PIK3CA and AKT1 
[9–11]. Thyroid cancer progression to PDC and ATC 
involves additional mutations that stimulate other cell 
signaling pathways, such as p53 and Wnt/β-catenin 
[12]. This latter pathway is constitutively activated in 
50% of PDC and ATC due to mutations in β-catenin and 
Axin genes [13–15]. These mutations impair normal 
β-catenin degradation, resulting in its accumulation in the 
cytoplasm and nucleus of tumor cells, and activation of 
target genes involved in biological functions essential for 
carcinogenesis [15–19].
Although no mutations in β-catenin or Axin have 
been identified in PTC or FTC, β-catenin dysregulation, 
particularly the reduction of β-catenin plasma membrane 
levels as well as its aberrant nuclear localization, closely 
parallel loss of tumor differentiation and poor prognosis in 
human samples [14].  
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These data suggest that additional mechanisms, 
including post-translational modifications, could be 
responsible for β -catenin mislocalization in thyroid tumors 
in the absence of mutations in Wnt components. The PI3K/
AKT pathway is traditionally linked to activation of the 
Wnt canonical pathway through the inhibition of GSK3β 
[20], which is a critical factor of the β-catenin destruction 
complex. GSK3β phosphorylates β-catenin at S33/37/T41, 
resulting in its ubiquitination and degradation through 
the proteasome. Recent evidence has shown that Akt 
can directly phosphorylate β-catenin at S552, leading to 
its stabilization and increasing its transcriptional activity 
[21, 22]. Moreover, PI3K signaling has been shown to 
control β-catenin activity in normal thyroid gland in 
response to TSH and IGFI [23]. In addition, the MAPK 
pathway has been described to activate Wnt signaling 
through ERK-mediated inhibition of GSK3β [24]. 
In an in vitro model of thyroid cancer, oncogenic 
RET/PTC, present only in PTC, induces β-catenin 
stabilization and nuclear accumulation by a Wnt-
independent mechanism involving activation of PI3K/
AKT and MAPK signaling pathways [25–27]. However, 
the consequences on β-catenin signaling in genetic 
contexts other than RET/PTC are unknown. Therefore, 
the aim of this work was to investigate whether other 
oncogenic drivers, such as RAS, BRAF or loss of PTEN, 
could activate the Wnt/β-catenin pathway and participate 
in thyroid carcinogenesis.
Here we show that HRAS, but not BRAF, induces 
β-catenin activation, unveiling a novel mechanism of 
β-catenin stabilization in thyroid tumor cells contingent 
on AKT activity. These findings strongly support the 
functional participation of β-catenin in cell proliferation 
and epithelial-mesenchymal transition (EMT), and suggest 
that it could be a potential therapeutic target for treatment 
of thyroid cancer.
RESULTS
RAS but not BRAF induces Wnt/β-catenin 
activation in thyroid cells
We investigated whether the Wnt/β-catenin pathway 
was active in the earliest steps of thyroid tumorigenesis 
driven by RAS and BRAF, the two main oncogenes 
in thyroid cancer [28]. To do this, we used rat thyroid-
derived PCCl3 cells conditionally expressing HRASV12 
(PC-HRAS) or BRAFV600E (PC-BRAF) after doxycycline 
treatment. As β-catenin stabilization is due in part to 
GSK3β inhibition, we examined GSK3β phosphorylation 
at Ser9. Doxycycline treatment for 48 h increased 
GSK3β levels in PC-HRAS cells but not in PC-BRAF 
cells, indicating that HRAS, but not BRAF, induced 
GSK3β inhibition (Figure 1A). To assess whether this 
inhibition modified β-catenin stabilization and its nuclear 
localization, we analyzed β-catenin expression in total, 
cytoplasmic and nuclear extracts from PC-HRAS and 
PC-BRAF cells treated or not with doxycycline. 
Whereas both HRAS and BRAF oncogenes induced 
a minor increase in total β-catenin levels (Figure 1B), 
only HRAS expression increased nuclear β-catenin 
expression (Figure 1C). These findings were confirmed by 
immunocytochemistry and confocal imaging (Figure 1D). 
To test whether β-catenin nuclear expression increased its 
transcriptional activity, PC-HRAS and PC-BRAF cells 
were transfected with the artificial Top/Fop promoter, 
which contains several β-catenin/TCF binding sites in 
tandem, and luciferase activity was measured. Cells 
were treated with LiCl as a positive control of β-catenin 
transcriptional activation. Expression of HRAS resulted 
in a robust and time-dependent increase in luciferase 
activity, reaching more than 10-fold at 48 h. By contrast, 
BRAF expression resulted in a minor increase (2-fold) in 
luciferase activity at 48 h after transfection (Figure 1E). 
To confirm that the reduced ability of BRAF to activate 
Top/Fop was not because of an overall reduced output 
of BRAF with respect to HRAS cells, we measured the 
ability of both oncogenes to activate the ERK effector 
ELK1. Expression of BRAF and HRAS induced the 
activation of ELK1 to a similar level (Figure 1F). These 
results show that HRAS, unlike BRAF, induces strong 
β-catenin stabilization and activation in thyroid cells.
PI3K stimulates β-catenin expression and 
activity in human thyroid tumor cells, which is 
dependent on its phosphorylation at Ser 552
To assess the status of Wnt/β-catenin signaling in 
human thyroid cancer, we surveyed β-catenin subcellular 
localization and transcriptional activity in a panel of 
human thyroid cell lines representative of the main 
histologic types, and harboring the main genetic mutations 
of thyroid cancer (Figure 2). Human HT29 colon 
carcinoma cells carrying the APC mutation [29] and Nthy-
ori 3–1 immortalized normal epithelial human thyroid cells 
[30] served as positive and negative controls, respectively. 
To assess the subcellular localization of β-catenin, we 
performed immunocytochemistry and confocal imaging 
(see Supplementary Figure 1 and summary in Figure 2A). 
According to the subcellular localization of β-catenin, we 
found three types of cells. One type expressed β-catenin 
exclusively in the plasma membrane (8505c, T238, Cal62 
and Nthy-ori 3–1). A second type expressed β-catenin 
both in the plasma membrane and in the cytoplasm, with 
a marked perinuclear accumulation (WRO and FRO). A 
third type of cell expressed β-catenin exclusively in the 
nucleus (FTC133, SW1736, Hth7, Hth83, C643, TPC1 
and KTC1), comparable with HT-29 colon carcinoma. 
Of note, the majority of RAS mutated cells (3 out of 4) 
presented β-catenin nuclear localization.
We next assessed β-catenin transcriptional activity 
(Figure 2B). Unexpectedly, no correlation was found 
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between the subcellular distribution of β-catenin and 
its transcriptional activity (Figure 2A, 2B). Generally, 
β-catenin transcriptional activity in thyroid cancer cell lines 
was lower ( 2̴-fold) than in HT-29 positive cells (5-fold). 
Notably, FCT133 cells, which harbor a PTEN deletion, had 
the greatest β-catenin transcriptional activity, up to > 3-fold.
Since FTC133 exhibited robust nuclear β-catenin 
expression and had the highest transcriptional activity, we 
used this cell line to examine the mechanisms of activation 
of β-catenin signaling. FTC133 cells derive from a 
follicular thyroid carcinoma, harbor a PTEN deletion and, 
accordingly, exhibit a high PI3K activity as shown by their 
high levels of AKT phosphorylation (Figure 3A). Western 
blotting of total cell extracts revealed high expression of 
total β-catenin in FTC133 cells (Figure 3A), which was 
comparable to its expression in HT-29 and TPC-1 cells, 
Figure 1: Wnt/β-catenin activation in PCCl3 cells conditionally expressing HRASV12 (PC-HRAS) or BRAFV600E 
(PC-BRAF). PC-HRAS and PC-BRAF cells were starved for 48 h and then treated with doxycycline for the times indicated. (A and B). 
Total proteins extracts were analyzed by western blot for the detection of p-GSK3β (panel A) and β-catenin (βcat) (panel B). (C) Nuclear 
(Nuc) and cytoplasmic (C) protein extracts were analyzed by western blot for the detection of β-catenin. CTCF and β-tubulin were used as 
nuclear and cytoplasmic loading controls, respectively. (D) Cells were grown on cover-slips, fixed and stained with a β-catenin antibody 
(red). Nuclei were stained with DAPI (blue). Scale bar 10 μm. (E) β-catenin transcriptional activity was measured in cells transfected with 
Super8x TopFlash (Top) or Super8x FopFlash (Fop) vectors after 24 and 48 h of doxycycline treatment or 48 h of LiCl treatment. Data 
show fold induction of the Top/Fop ratio with respect to non-treated cells (−). (F) ELK-1 activation was measured in cells transfected with 
the reporter vector pGE51-luc, encoding the transactivation domain of Elk-1 (amino acids 307 to 428) fused to the GAL4 DNA-binding 
domain, and a pRL-CMV Renilla construct, after 48 h in the presence (+) or absence (−) of doxycycline. Data show fold induction of ELK-1 
activation relative to Renilla levels. Values represent means ± SEM (n = 3). *p < 0.05; **p < 0.01; *** p < 0.001.
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two cell types exhibiting β-catenin activation [25, 31]. 
Interestingly, FTC133 also showed high levels of β-catenin 
phosphorylated at Ser552, which promotes β-catenin entry 
into the nucleus and increases its transcriptional activity 
(Figure 3A) [21, 32]. We previously reported that TSH and 
IGF1, through PKA and AKT, respectively, phosphorylate 
β-catenin at Ser552 in normal differentiated PCCl3 
thyroid cells [23]. In thyroid tumor cells, the cAMP/PKA 
pathway is impaired due to oncogene activation [33, 34]. 
To determine whether β-catenin phosphorylation was a 
direct consequence of PI3K/AKT activation, FTC133 
cells were treated with Akti1/2, a specific AKT inhibitor, 
and phospho-Ser552 β-catenin levels were measured. AKT 
inhibition decreased phospho-Ser552 β-catenin expression 
(Figure 3B) and subsequent β-catenin transcriptional 
activity (Figure 3C). By contrast, MAPK/MEK inhibition 
failed to suppress β-catenin transcriptional activity in 
FTC133 cells (Figure 3C). In HT-29 cells, which do not 
have a constitutively active PI3K pathway (Figure 3A), 
the transcriptional activity of β-catenin was unaffected 
by AKT inhibition (Figure 3C). Consistent with these 
results, confocal imaging showed that phospho-Ser552 
β-catenin was localized in the nuclei of FTC133 cells and 
its presence was contingent on AKT activity (Figure 3D).
In light of these findings and since BRAFV600E 
oncogene activates MAPK pathway and HRASV12 
oncogene activates both MAPK and PI3K pathways, we 
evaluated phospho-Ser552 β-catenin levels in PC-BRAF 
and PC-HRAS cells. HRAS but not BRAF activation 
increased phospho-Ser552 β-catenin levels in PCCl3 
cells (Figure 3E). In agreement with this finding, whereas 
RAS mutant human cell lines (Hth7 and C643) expressed 
phospho-Ser552 β-catenin that was dependent on AKT 
activity (Figure 3F), the BRAF mutant cell line BCPAP 
did not. These data strengthen the notion that PI3K/AKT 
stabilizes β-catenin in thyroid cancer. 
PI3K/AKT-mediated phosphorylation of β-catenin 
at Ser552, unlike phosphorylation at the N-terminus, 
increases its stabilization, leading to its accumulation 
and translocation into the nucleus [22]. To test if this 
mechanism was indeed responsible for β-catenin 
stability in FTC133 cells, we used bortezomib to inhibit 
proteasome activity and co-treated cells with/without 
Akti1/2 to inhibit AKT activity. Western blotting showed 
that the degradation of total β-catenin after AKT inhibition 
was impaired with bortezomib and, thus, dependent on 
proteasome activity (Figure 3G). This result shows that 
phosphorylation at Ser552 is essential for AKT-induced 
β-catenin stabilization. 
Finally, to examine whether the canonical Wnt 
pathway participated in PI3K/AKT-mediated stabilization 
of β-catenin, we inhibited Wnt signaling in FTC133 cells 
with XAV939 [35]. Inhibition had no effect on phospho-
Ser552 β-catenin levels, suggesting that PI3K/AKT-
mediated stabilization of β-catenin is independent of Wnt. 
However, inhibition of Wnt signaling decreased total 
β-catenin expression and increased phospho-Ser33/37/T41-
β-catenin, an N-terminal phosphorylation that promotes 
β-catenin degradation (Figure 3G) [35]. By contrast, 
inhibition of AKT had no effect on phosphorylation at 
Figure 2: β-catenin subcellular localization and transcriptional activity in a panel of human thyroid cancer cell lines. 
(A) Table summarizing classification, mutations described and β-catenin localization in different thyroid cell lines. β-catenin localization 
was analyzed by immunocytochemistry and confocal imaging as shown in Supplementary Figure 1. (B) β-catenin transcriptional activity 
was measured in Super8x (Top) or Super8x FopFlash vector-transfected cells. Data show fold induction of the Top/Fop ratio with respect 
to non-treated cells (−). Values represent means ± SEM (n = 3). 
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Figure 3: PI3K/AKT signaling controls β-catenin expression through its phosphorylation at serine 552. (A, B) β-catenin 
and pβ-cateninS552 expression levels were analyzed by western blot in the indicated cell lines and in FTC133 cells treated with DMSO 
or with Akti1/2 for the specified times. (C) β-catenin transcriptional activity was analyzed in FTC133 and HT29 cells after treatment with 
DMSO, Akti1/2 or UO126 for 24 h. Data show fold induction of the Top/Fop ratio with respect to non-treated cells (−). Values represent 
means ± SEM (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001. (D) FTC133 cells were grown on cover-slips, treated with DMSO or Akti1/2 
for 24 h, fixed and stained for pβ-cateninS552 (green). Nuclei were stained with DAPI (blue). Scale bar 25 μm. The insets show higher 
magnifications of the regions marked by a square. (E) PC-HRAS and PC-BRAF were starved for 48 h and then treated with doxycycline 
for 48 h. Total protein extracts were analyzed by western blot for pβ-cateninS552. (F) The indicated cell lines were treated with DMSO 
or Akti1/2 and total protein extracts were analyzed by western blot for the detection of β-catenin and pβ-cateninS552. (G) Left panel: 
FTC133 cells were pre-treated for 1 h with bortezomib (Bortz) and then treated with DMSO, Akti1/2 or XAV939 (XAV) for 8 h. Total 
protein extracts were analyzed by western blot for the detection of pβ-cateninS552 and pβ-cateninS33/37/T41. Right panel: quantification 
of protein levels normalized to β-actin. Values represent means ± SEM (n = 3). *p < 0.05; **p < 0.01; ns not significant.
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the N-terminus. Collectively, these results suggest that 
PI3K/AKT and Wnt induce β-catenin stabilization through 
independent mechanisms in thyroid cancer cells that is 
dependent on its phosphorylation status, similar to that 
described in normal thyroid cells [23].
Overall, these data support a critical function 
for PI3K/AKT signaling, but not MAPK signaling, in 
β-catenin stabilization in thyroid tumor cells. This PI3K/
AKT-controlled stabilization of β-catenin occurs through 
its phosphorylation at Ser552 and is independent of Wnt.
β-catenin silencing inhibits proliferation and 
induces senescence in human thyroid tumor  
cells
To study the role of β-catenin in thyroid tumor 
cell proliferation, we used a lentivirus expressing a short 
hairpin RNA (shRNA) to stably silence β-catenin in 
FTC133 cells (Figure 4A). As expected, the level of DNA 
synthesis in β-catenin shRNA cells was decreased by 50% 
relative to scrambled shRNA-transfected cells (Figure 4B). 
This was paralleled by a decrease in proliferation of 
β-catenin shRNA cells (Figure 4C). Similarly, a significant 
decrease in DNA synthesis was detected in β-catenin 
shRNA-transfected RAS mutant thyroid cancer cell lines 
(C643, Hth83, and Hth7) (Figure 4D). To confirm that 
this effect was due to β-catenin transcriptional activity 
and not because of its role in cell adhesion, we stably 
expressed a dominant-negative form of FLAG-tagged 
TCF4 (Transcription factor 7-like 2 gene) in FTC133 
cells, which does not bind β-catenin [36], and measured 
DNA synthesis. BrdU incorporation was significantly 
lower in TCF4-expressing cells than in controls (Figure 
4B), suggesting that FTC133 cell proliferation required 
the transcriptional activity of β-catenin independent of its 
involvement in cell adhesion. 
Since cyclinD1 is a direct downstream target of 
β-catenin activation, we sought to study its function in 
cell proliferation. Unexpectedly, silencing of β-catenin 
markedly increased cyclin D1 levels (Figure 5A) 
and also the levels of the cell cycle inhibitors p27kip1 
and p21 (Figure 5A, 5B). This surprising result led 
us to hypothesize that the high expression of cyclin 
D1 and cell cycle inhibitors were in fact indicators of 
senescence. Indeed, previous studies have demonstrated 
that upregulation of cyclinD1 occurs in senescent cells 
[37–39]. Thus, we determined β-galactosidase (SA-β-gal) 
Figure 4: β-catenin inhibition decreases proliferation in human tumoral thyroid cells. (A) FTC133 cells were infected with 
control (shScr) or β-catenin (shβcat) lentivirus shRNAs. Total protein extracts were obtained at the indicated times and analyzed by western 
blot for β-catenin expression. (B) Left panel: FTC133 cells were infected with control (shScr) or β-catenin (shβcat) lentivirus shRNAs or a 
dominant-negative form of TCF4 [dnTCF4] and BrdU incorporation was calculated. Data show BrdU incorporation relative to that of cells 
infected with the vehicle vector (shScr). Values represent means ± SEM (n = 3). ***p < 0.001. Right panel: western blot analyis of TCF4 
expression (C) FTC133 cells were infected with control (shScr) or β-catenin (shβcat) lentivirus shRNAs and cell growth was estimated 
relative to the density at day 0. Values represent means ± SEM (n = 3). (D) Cell lines were infected with control (shScr) or β-catenin (shβcat) 
lentivirus shRNAs and BrdU incorporation was calculated. Data show BrdU incorporation relative to that of the cells infected with the 
vehicle vector (shScr). ***p < 0.001.
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activity as a metric of senescence. Silencing of β-catenin 
resulted in a significant increase in the percentage of SA-β-
gal-positive cells relative to non-silenced controls (Figure 
5C). Comparable results were obtained in β-catenin-
silenced C643 and Hth7 cells (Figure 5D), demonstrating 
that β-catenin silencing also increases senescence in RAS 
mutant human thyroid cell lines. 
To verify this finding in vivo, we injected control 
or β-catenin shRNA FTC133 cells subcutaneously into 
immunocompromised NOD-SCID mice and monitored 
the development of xenografts. Xenograft tumor size was 
dramatically reduced in β-catenin-silenced tumors with 
respect to the control tumors (Figure 5E). Importantly, 
the expression levels of β-catenin remained inhibited in 
xenografts of β-catenin-silenced cells compared with 
the control cells (Figure 5F). Collectively, these results 
strongly suggest that inhibition of β-catenin activity 
decreases thyroid tumor cell proliferation by promoting 
cell cycle arrest and inducing senescence.
β-catenin silencing induces E-cadherin 
expression and diminishes EMT markers 
expression and tumor cell invasion
A feature common to epithelial tumor cells is the 
acquisition of a mesenchymal phenotype characterized by 
an increased invasion capacity. Epithelial-mesenchymal 
transition (EMT) is induced by many signaling pathways 
including Wnt/β-catenin and is characterized by the 
loss of E-cadherin expression through activation of 
transcriptional repressors such as β-catenin/TCF, Snail, 
Slug, TWIST or ZEB1/2 [40]. Inhibition of E-cadherin 
expression has been described in BRAF-driven thyroid 
tumors in which the MAPK pathway is activated [41], 
but little is known about the mechanisms involved in 
E-cadherin repression in RAS-driven tumors where PI3K/
AKT is activated. Given our findings of PI3K regulation 
of β-catenin activity, we examined its role on E-cadherin 
expression in FTC133 thyroid cells. Silencing of β-catenin 
resulted in an increase in E-cadherin protein and mRNA 
expression (Figure 6A, 6B). This was accompanied by a 
decrease in the expression of transcription factors Slug and 
Twist, which are also controlled by β-catenin/TCF [42]. 
Similarly, the expression of EMT target genes N-cadherin 
and ZEB1 [43] were also reduced in β-catenin-silenced 
cells (Figure 6B). Interestingly, although not a target gene 
of the β-catenin/TCF complex, silencing of β-catenin in 
FTC133 markedly decreased Snail expression, whereas 
the expression of other mesenchymal genes such as 
fibronectin or vimentin was unchanged (Figure 6B). As 
EMT is ultimately responsible for tumor cell migration 
and invasion, we examined the invasion capacity of 
β-catenin-silenced FTC133 cells using Matrigel assays. 
As anticipated, these cells exhibited a significant 3-fold 
reduction in their invasiveness with respect to the control 
scramble cells (Figure 6C).
DISCUSSION
We show that RAS but not BRAF signals through 
β-catenin and controls essential oncogenic functions in 
thyroid cancer cells. HRAS acts predominantly through 
PI3K/AKT to stabilize β-catenin via two mechanisms, 
GSK3β inhibition and direct β-catenin phosphorylation at 
Ser552. PI3K/AKT-mediated β-catenin activation protects 
cells from senescence and increases cell proliferation, 
EMT and cell invasion. 
Mutations in β-catenin have been identified in the 
most aggressive forms of thyroid cancer, such as poorly 
differentiated and anaplastic carcinomas. In addition, 
aberrant expression of β-catenin and its abnormal 
cellular localization in the cytoplasm and nucleus occur 
in tumor cells of differentiated thyroid cancer [14] and, 
in accordance with our findings, correlates with the 
presence of oncogenic RAS [14]. The consequences of 
this dysregulation as well as the functional implications 
of β-catenin activating mutations are of great interest 
due to the potential impact on pathogenesis. Studies on 
melanoma, a cancer in which β-catenin is also activated, 
suggest that the results of Wnt/ β-catenin signaling 
activation are complex and likely context-dependent [44]. 
Similarly, we show here that in the context of precisely 
defined genetic changes, such as RAS and PTEN loss, 
β-catenin is stabilized and expressed in the nucleus and 
mediates pro-oncogenic effects including evasion from 
oncogene-induced senescence, EMT and invasion.  
An improved understanding of thyroid cancer 
genetics is beginning to pave the way for the molecular 
classification of these tumors based on fundamental 
driving mutations. PTC is a MAPK-driven cancer that 
has two mutually exclusive drivers with distinct signaling 
outcomes: BRAFV600E and mutated RAS. Tumors driven 
by BRAFV600E have high MAPK-signaling and tumors 
driven by RAS and receptor tyrosine kinase fusions 
(e.g. RET/PTC) have low MAPK-signaling and have 
concurrent activation of PI3K/AKT [28] [45]. FTC 
is considered predominantly driven by PI3K/AKT 
activation through mutations in RAS, PTEN and RASL1 
loss, or by activating mutations in PIK3CA and AKT1 
[10, 46]. Overlapping mutations in components of both 
pathways have been found in the full metastatic thyroid 
cancer phenotype [47, 48]. The interaction of β-catenin 
with these oncogenic driver mutations is of great interest 
as it may determine the fate of the tumor. In transgenic 
melanoma models, concurrent BRAFV600E and PTEN loss 
requires β-catenin stabilization to promote metastasis to 
lymph nodes and lungs [44]. By contrast, in the presence 
of wild-type PTEN, BRAFV600E tumors do not metastasize 
independently of β-catenin status. Here we show that 
mutated RAS-driven thyroid tumors need β-catenin 
stabilization for tumor progression and this effect requires 
PI3K/AKT activation and is independent of MAPK 
signaling. 
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It has previously been demonstrated that oncogenic 
RET/PTC rearrangements stabilize β-catenin, promoting 
its accumulation in the nucleus and enhancing its activity 
[25]. Similar to RAS, RET/PTC also results in lower 
MAPK-signaling and activation of PI3K/AKT [25, 28]. 
In the presence of RET/PTC rearrangements, the group 
of Santoro observed that β-catenin stabilization induces 
a mitogenic effect through the upregulation of TCF/LEF-
induced cyclin D1 [49]. By contrast, in the presence of 
RAS or PTEN loss, we found a strong upregulation 
of cyclin D1 following β-catenin silencing. Cyclin D1 
upregulation is an established marker of senescence 
and, accordingly, we found that β-catenin silencing 
induced senescence. The reasons for this discrepancy 
between RET/PTC and RAS/PTEN loss remain 
incompletely understood. A possible explanation is that 
in our experiments we achieved a much greater β-catenin 
silencing than obtained by Castellone et al. [25] and this 
may be necessary to induce senescence. Additionally, 
these differences also emphasize that defining the 
biological effects of β-catenin signaling in thyroid cancer 
may not be possible out of the context of other mutational 
changes and should help to better classify thyroid cancer 
into biologically meaningful groups.  
Although human thyroid cancer cells with RAS 
mutations or PTEN loss show strong β -catenin nuclear 
localization, there is only a modest activation of the β-cat/
TCF reporter relative to cells without β-catenin in the 
nucleus (Figure 2). β-catenin is a transcriptional regulator 
that cannot bind DNA by itself and requires binding to 
Figure 5: β-catenin inhibition induces cell senescence and reduces tumor growth in human tumoral thyroid cells. 
(A) FTC133 cells were infected with control (shScr) or β-catenin (shβcat) lentivirus shRNAs. Left panel: total protein extracts were 
obtained and analyzed by western blot for the detection of β-catenin, cyclinD1 and p27. Right panel: quantification of cyclinD1 and p27 
protein levels normalized to β-actin. Values represent means ± SEM (n = 3). (B) p21 mRNA expression levels were analyzed in FTC133 
shScr and shβcat-infected cells. (C) FTC133 cells were infected with control (shScr) or β-catenin (shβcat) lentivirus shRNAs and analyzed 
for SA-βgal-positivity. Left panel: representative βgal-staining. Right panel: percentage of SA-βgal positive cells per field. Values represent 
means ± SEM (n = 3). **p < 0.01. (D) C643 and Hth83 cells were infected with control (shScr) or β-catenin (shβcat) lentivirus shRNAs 
and analyzed for SA-βgal-positivity. Percentage of SA-βgal positive cells per field. Values represent means ± SEM (n = 3). **p < 0.01. 
(E) FTC133 control (shScr) or shβcat cells were injected in NOD-SCID mice and the tumor volume was measured at the end of the 
experiment. Values represent means ± SEM (n = 3). **p < 0.01. (F) FTC133 grafts from control (shScr) or shβcat cells were stained with a 
β-catenin antibody (red). Nuclei were stained with DAPI (blue). Scale bar 25 μm.
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other transcription factors to increase the expression 
of its target genes. Even though TCF/LEF transcription 
factors are the most studied β-catenin partners, growing 
evidence suggest that β-catenin can associate with other 
DNA-binding transcription factors, such as FoxO1 [50], 
the nuclear receptor LRH1 [51] or the thyroid transcription 
factor Pax8 [23]. Differential expression of those factors 
in thyroid cells lines could explain the variable β-catenin 
transcriptional activity found herein. Future studies will be 
necessary to identify β-catenin target genes in the thyroid-
specific context. 
Another interesting observation is that Cal62 cells, 
which harbor a K-RAS mutation, present β-catenin in the 
membrane, while cells harboring H or N-RAS mutations 
show nuclear β-catenin localization. RAS isoforms are 
functionally non-redundant, mainly due to their different 
subcellular localization, and it has been shown that K-RAS 
signals preferentially via BRAF/MAPK while the other 
isoforms have PI3K as their main effector [52].
How β-catenin is activated may have important 
functional implications for its potential use as a therapeutic 
target. In addition to GSK3β inhibition, Castellone’s 
work demonstrated RET-induced phosphorylation in 
β-catenin at Tyr654 residue. This phosphorylation event is 
dependent on tyrosine kinase receptors, such as ERB and 
SRC [53, 54], but has no relationship with AKT activation. 
By contrast, in a RAS-like genetic context where PI3K/
AKT activation is present, phosphorylation of β-catenin at 
Ser552 seems to be predominant and is very sensitive to 
AKT inhibition. Ser552 phosphorylation has been shown 
to be independent of Wnt factors and MAPK signaling. 
Thus, strategies to inhibit these signaling pathways may 
have a very limited effect on β-catenin activation in 
RAS-like tumors, whereas AKT inhibition and/or direct 
inhibition of β-catenin Ser552 phosphorylation could be 
a more specific mechanism to inhibit its pro-metastatic 
effects.
Components of the MAPK and PI3K/AKT signaling 
pathways are important molecular targets for new cancer 
therapeutics. For example, selumetinib (a MEK inhibitor) 
and vemurafenib and dabrafenib (mutant BRAF inhibitors) 
are clinically beneficial in thyroid cancer patients with 
advanced metastatic disease. However, resistance to 
kinase inhibitors targeting components of these signaling 
pathways is a common phenomenon in patients with 
advanced radioactive iodine-refractory differentiated 
thyroid cancer [55]. Understanding how simultaneous 
activation of additional signaling pathways in a given 
tumor can impact inhibitor-targeted pathways is essential 
and may assist in explaining why some patients with a 
given driver mutation respond differentially to treatment 
with the same inhibitor. In this context, it is particularly 
noteworthy that changes in β-catenin can have such 
significant effects in RAS-driven tumors. 
Figure 6: β-catenin silencing decreases expression of EMT markers and inhibits cell migration of human thyroid 
tumoral cells. (A) FTC133 cells were infected with control (shScr) or β-catenin (shβcat) lentivirus shRNAs. Total protein extracts were 
analyzed by western blot for the detection of β-catenin and E-cadherin. (B) Expression of selected EMT genes. Data show the relative 
expression levels compared with the control cells. (C) The invasive capacity of FTC133 control or shβ-catenin cells was analyzed in 
Matrigel-coated Transwells. Left panel: number of cells invading the lower chamber after 24 h. A total of 10 fields for each cell line were 
quantified. Values represent means ± SEM (n = 3).**p < 0.01. Right panel: representative images of Transwell filters.
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In conclusion, we provide new insights into the 
mechanisms by which alterations in β-catenin signaling 
impact thyroid cancer formation and progression. 
Depending on the genetic context (RAS-driven tumors and 
those where PI3K/AKT is predominantly activated such as 
PTEN-deficient tumors), β-catenin is stabilized specifically 
through phosphorylation at Ser552 and this event protects 
cells from oncogene-induced senescence and contributes 
to EMT and cell invasion. β-catenin targeting approaches 
could therefore have potential utility in thyroid cancer, 
particularly in combination with other therapies. Given 
the interconnectedness of β-catenin signaling with other 
oncogenes and tumor suppressor pathways, further studies 
are clearly necessary to explore the potential value of 
combinatorial therapies. We believe that our study, together 
with those reported by Castellone et al. [17] and Gujral et al. 
[56], will help to identify the genetic factors and biomarkers 
that can predict responses to treatment with β-catenin 
pathway modulators, either alone or in combination with 
other therapies, and will be an important next step in 
determining the utility of these potential new therapies.
MATERIALS AND METHODS
Cell culture
HeLa and HEK293T cell lines were grown 
in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 5% and 10% fetal bovine serum 
(FBS), respectively. PC-BRAF and PC-HRAS were 
derived from PCCl3 rat thyroid follicular cells [57] to 
obtain doxycycline-inducible expression of BRAFV600E 
or HRASV12 [58, 59]. Cells were grown in Coon’s 
modified Ham’s F-12 medium supplemented with a six-
hormone mixture (1 nM TSH, 10 μg/ml insulin, 10 ng/ml 
somatostatin, 5 μg/ml transferrin, 10 nM hydrocortisone, 
and 10 ng/ml glycyl-L-histidyl-L-lysine acetate) and 5% 
donor calf serum (complete). To avoid the effects of TSH 
and IGF1 on the Wnt signaling pathway [23], PC-HRAS 
and PC-BRAF cells were transferred to Coon’s starvation 
medium supplemented with 0.2% BSA plus hormones, 
but without TSH and insulin for 48 h. Cells were treated 
with 1 μg/mL doxycycline for the indicated time periods 
to induce BRAF or HRAS expression.
Thyroid cancer cell lines were from the following 
sources: C643, Hth7, Hth83 and SW1736 were originally 
from Dr. N.E. Heldin (University of Uppsala, Uppsala, 
Sweden); BCPAP was from Dr. M. Santoro (University of 
Federico II, Naples, Italy); FTC133 and Nthy-Ori-3.1 were 
obtained from the European Collection of Cell cultures; 
WRO-82-1 was from Dr. G. J. F. Juillard (University of 
California-Los Angeles School of Medicine, Los Angeles, 
CA); TPC1 was provided by Dr. A.P. Dackiw (Johns 
Hopkins University, Baltimore, Maryland); KTC-1 was 
provided by Junichi Kurebayashi (Kawasaki Medical 
School, Japan); CAL62, FRO and 8505c were obtained 
from the Leibniz-Institut DSMZ-German Collection of 
Microorganisms and Cell Cultures and T238 was from 
Dr. Lucia Roque (Portuguese Cancer Institute, Lisbon, 
Portugal). Cell lines were authenticated every 6 months 
by short tandem repeat (STR) profiles using the Applied 
Biosystems Identifier kit in the Genomic Facility at the 
Instituto de Investigaciones Biomédicas (Madrid, Spain). 
Cell lines were grown at 37ºC in RPMI 1640 with 10% 
FBS, except FTC133, which was cultured in DMEM. The 
following inhibitors were added to cells at the indicated 
concentrations: 10 µM UO126 (Calbiochem), 10 µM AKT-
i-VIII, 10 µM XAV939 and 10 µΜ bortezomib (Sigma).
Luciferase reporter assay 
To measure β-catenin transcriptional activity, cells 
were transfected with Super8xTop- and Fop-Luc luciferase 
vectors, which contain 8 optimized and 8 mutated TCF-
binding sites, respectively (both kind gifts of R.T. Moon) 
[60]. To measure ERK activity, cells were transfected 
with the reporter pGE51-luc and a vector encoding the 
transactivation domain of Elk-1 (amino acids 307 to 
428) fused to the GAL4 DNA-binding domain [61]. 
Additionally, a pRL-CMV Renilla luciferase construct 
(Promega) was co-transfected to monitor transfection 
efficiency. HRASV12 and BRAFV600E expression vectors 
were used in transfection experiments as described [62]. 
Thyroid cancer cells were grown in DMEM or 
RPMI and transfected with JetPEI transfection reagent 
(Polyplus). Twenty-four hours after transfection, cells 
were treated with the indicated compounds for 24 h and 
harvested for luciferase measurement (Dual-Luciferase 
kit, Promega). PC-BRAF and PC-HRAS cells were 
transfected in Coon’s complete medium using JetPEI or 
by calcium phosphate coprecipitation [63], grown for 48 h 
in starvation medium and treated with doxycycline for the 
indicated time periods. HeLa cells were grown in DMEM 
complete medium, transfected by calcium phosphate 
coprecipitation, and harvested 48 h later. One microgram 
of promoter construct was co-transfected with 1 μg of 
the indicated expression vector. The amount of DNA 
in each transfection was kept constant by the addition 
of an appropriate amount of empty expression vector, 
pcDNA3.1. To normalize transfection efficiency, 50 ng of 
pRL-CMV vector was added in all cases. Additionally, in 
the Top/Fop assays, Top activity was normalized with Fop 
activity to ensure that Top Flash values were dependent on 
the Lef1/Tcf-binding sites in the promoter. All transfection 
experiments were performed in triplicate and carried out 
at least three times.
Western blotting 
Total proteins were lysed in a buffer containing 1% 
NP-40, 0.1% SDS, 0.5% deoxycholic acid, supplemented 
with a protease inhibitor cocktail (Roche). Nuclear 
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and cytoplasmic proteins were extracted as described 
[64]. Protein concentration was measured according 
to the method of Bradford [65] using an assay from 
Bio-Rad Laboratories. Equal amounts of protein were 
diluted in loading buffer and heated at 95ºC for 5 min. 
Samples were separated by SDS-PAGE, transferred 
onto nitrocellulose membranes, blocked and incubated 
overnight with primary antibodies diluted in PBS 0.1% 
Tween 20 containing 5% w/v nonfat dry milk. Antibody 
binding was revealed with horseradish peroxidase (HRP)-
conjugated secondary antibodies and immunoreactive 
proteins were visualized by enhanced chemiluminescence 
(Thermo Scientific). Protein expression levels were 
quantified using ImageJ software (NIH) and normalized to 
their loading controls. Antibodies to streptavidin-(HRP), 
AKT1/2, pAKT (S473), β-actin, β-catenin, cyclin D1, 
p27, pERK (Y204), ERK1/2 and tubulin were obtained 
from Santa Cruz Biotechnology. Antibodies to phospho-
β-catenin (S33/37/T41 and S552), CTCF and phosph-
GSK3β (S9) were from Cell Signaling Technology 
Antibodies to E-cadherin and GSK3β were from BD 
Biosciences. 
Semi-quantitative RT–PCR
RNA was extracted using Trizol (Sigma) and equal 
amounts of RNA were added to a reverse-transcriptase 
reaction mix (m-MLV, Promega). Real time PCR was 
performed on an Mx3000 platform (Agilent) using the 
FastStart Universal Probe Master kit (ROX, Roche) 
and run for 40 cycles. Specificity of the reactions was 
determined by subsequent melting curve analysis. 
Stratagene analysis software was used to remove 
background fluorescence [66]. The number of cycles 
needed to reach the crossing point for each sample was 
used to calculate the amount of each product using the 
2–∆∆Ct method. The levels of PCR product were expressed 
as a function of actin. The primers used are listed in 
Supplementary Table 1.
Immunofluorescence
Cells were seeded onto coverslips and treated as 
indicated. Unfixed tumors were embedded in OCT (Tissue 
tek). Frozen tissue was sectioned (10 μm, Leica cryostat) 
and mounted on SuperFrost Plus slides (Fisher). Cells and 
frozen sections were fixed with 4% paraformaldehyde in 
PBS pH 7.4 for 10 min, rinsed with PBS, permeabilized 
with 0.5% Triton X-100, and blocked with 1% BSA. After 
over-night incubation with primary β-catenin (C-18) 
or phospho-Ser552 β-catenin antibodies [67] (provided 
by Dr. Linheng Li), samples were rinsed with PBS and 
incubated with Alexa 488 or Texas Red 546 secondary 
antibodies for one hour, mounted with ProLong® Gold 
antifade reagent with DAPI (Invitrogen) and observed 
under a confocal microscope with a 63× magnification 
objective (Leica).
Lentivirus production and cell infection
Stable thyroid cancer cell lines were generated 
using lentiviral expression vectors. For the generation 
of β-catenin-silenced cells (shβ-cat) the vector encoded 
an shRNA against human βcatenin (pLKO.1-shbcat; 
Open Biosystem clone TRCN0000003845). Control 
cells (shScramble) were infected with virus containing 
a non-coding control DNA (pGIPZ-shscramble, Open 
Biosystem). Cells expressing a dominant negative form 
of TCF (dnTCF4) were generated using the vector EdTP 
(vector was from Addgene and is described in [36]). 
VSV-G pseudotyped lentivirus production was performed 
as previously described [23]. Forty-eight hours after 
infection, puromycin-resistant cells were selected with 
1 μg/ml of puromycin (Sigma).
Cell proliferation and BrdU incorporation assay
To determine cell proliferation cells were plated at 2 
× 105 cell per well in 24-well plates. Cells were fixed at the 
indicated times with 1% glutaraldehyde and stained with 
crystal violet. After extensive washing, crystal violet was 
resolubilized in 1% acetic acid and quantified at 595 nm 
as an indirect measure of cell number. DNA synthesis 
was determined using the Cell Proliferation ELISA BrdU 
Assay (Roche Molecular Biochemicals). Briefly, cells were 
seeded in 96-well plates (5 × 103 cells/well). Twenty-four 
hours later, cells were pulse labeled for 2 h with 10 µM 
BrdU, and measurements were carried on an ELISA reader 
at 450 nm. Experiments were performed three times in 
triplicate.
Senescence assay (SA-β-gal staining) 
Thyroid cells were infected and selected and plated 
on 12-well plates (7 × 105 cells/well). Twenty-four hours 
later, cells were fixed and assayed for SA-β-gal activity 
using the Senescence Detection kit (BioVision). To obtain 
the percentage of SA-β-gal positive cells, four images of 
each condition were captured using 10× magnification and 
quantified. Experiments were repeated at least three times.
Invasion assay
Invasion was measured in Transwell cell culture 
chambers using BD BioCoat Matrigel Invasion Chambers 
(BD Bioscience). Infected FTC133 cells (2.5 × 104) were 
placed on the upper chamber in DMEM plus 0.2% FBS. 
The lower chamber contained DMEM supplemented with 
15% FBS. Cells were allowed to invade for 24 h at 37ºC 
and 5% CO2. Nonmigrated cells on the upper chamber 
were removed with a cotton swab; filters were fixed in 4% 
paraformaldehyde and stained using the Diff-Quik staining 
kit (BD Biosciences). The total number of cells migrated 
to the lower surface was counted. The experiments were 
repeated three times.
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Xenograft studies in mice
Protocols for animal handling were approved by 
the Institutional Animal Care Committee, following the 
rules of the European Union and the National Institutes 
of Health. Animals were housed in temperature-controlled 
rooms (22 ± 2oC) with 12-h light/dark cycles (lights on 
at 07:00 h) and had free access to food and water. For 
xenograft studies 9 × 106 FTC133 shScramble or shβ-cat 
cells were subcutaneously injected into two-month-old 
female NOD-SCID mice. Tumors were measured every 
4 days and the tumor volume was calculated as π*l*w/6, 
where l = length in mm and w = width in mm. 
Statistical Analysis
Results are presented as mean fold induction ± SEM 
from at least three independent biological experiments. 
Student’s two-tailed t-test was used to assess differences 
between measurements. Differences were considered 
statistically significant if p < 0.05.
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